Use of biologic treatment in psoriasis patients with HIV: A systematic review

To the Editor: Psoriasis is a chronic condition characterized by T helper (Th)-17-centerd immune dysregulation. 1 Kagami S. Rizzo H.L. Lee J.J. Koguchi Y. Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010; 130: 1373-1383https://doi.org/10.1038/jid.2009.399 Abstract Full Text Full Text PDF PubMed Scopus (538) Google Scholar Despite increasing use of targeted biologics, limited guidance exists for psoriasis patients living with HIV (PPLHIV). 2 Menter A. Gelfand J.M. Connor C. et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020; 82: 1445-1486https://doi.org/10.1016/j.jaad.2020.02.044 Abstract Full Text Full Text PDF PubMed Scopus (184) Google Scholar ,3 Lambert J.L.W. Segaert S. Ghislain P.D. et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020; 34: 1914-1923https://doi.org/10.1111/jdv.16683 Crossref PubMed Scopus (24) Google Scholar This systematic review examines evidence surrounding this indication.